Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 1, 2008, Pages 118-127

  Zhu, Hai Lei ^a   Brain, Keith L ^b   Aishima, Manami ^a   Shibata, Atsushi ^a   Young, John S ^b   Sueishi, Katsuo ^a   Teramoto, Noriyoshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; 1 METHYL 4 PIPERIDYL BENZILATE N OXIDE; 1 METHYL 4 PIPERIDYL DIPHENYLPROPOXYACETATE N OXIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM ION; CARBACHOL; DRUG METABOLITE; GUANINE NUCLEOTIDE BINDING PROTEIN; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NIFEDIPINE; OTENZEPAD; PIRENZEPINE; PROPIVERINE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; AMPLITUDE MODULATION; ANIMAL CELL; ANTICHOLINERGIC EFFECT; ARTICLE; BLADDER EPITHELIUM; BLADDER MUSCLE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSFORMATION; ELECTRIC FIELD; ELECTROSTIMULATION; INHIBITION KINETICS; MALE; MOUSE; MUSCLE CELL; NONHUMAN; OVERACTIVE BLADDER; PATCH CLAMP; PRIORITY JOURNAL; STEADY STATE;

ANIMALS; BENZILATES; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CHOLINERGIC ANTAGONISTS; CYCLIC N-OXIDES; ELECTRIC STIMULATION; MALE; MICE; MICE, INBRED BALB C; MYOCYTES, SMOOTH MUSCLE; PATCH-CLAMP TECHNIQUES; RECEPTOR, MUSCARINIC M3; URINARY BLADDER;

EID: 37349062752     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.130021     Document Type: Article

References (29)

1. Andersson KE, Appell R, Cardozo LD, Chapple C, Drutz HP, Finkbeiner AE, Haab F, and Vela Navarrete R (1999) The pharmacological treatment of urinary incontinence. BJU Int 84:923-947.
2. Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Schubert G, Mürtz G, Frank M, and Wieners F (2000) Efficacy and cardiac safety of propiverine in elderly patients: a double-blind, placebo-controlled clinical study. Eur Urol 37: 702-708.
3. Eglen RM, Hedge SS, and Watson N (1996) Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 48:531-565.
4. Fry CH, Skennerton D, Wood D, and Wu C (2002) The cellular basis of contraction in human detrusor smooth muscle from patients with stable and unstable bladders. Urol 59 (Suppl. 1):3-12.
5. Hashitani H, Fukuta H, Takano H, Klemm MF, and Suzuki H (2001) Origin and propagation of spontaneous excitation in smooth muscle of the guinea-pig urinary bladder. J Physiol 530:273-286.
6. Haustein KO and Hüller G (1988) On the pharmacokinetics and metabolism of propiverine in man. Eur J Drug Metab Pharmacokinet 13:81-90.
7. Herbison P, Hay-Smith J, Ellis G, and Moore K (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 326:841-844.
8. Kajioka S, Nakayama S, Asano H, and Brading AF (2005) Involvement of ryanodine receptors in muscarinic receptor-mediated membrane current oscillation in urinary bladder smooth muscle. Am J Physiol Cell Physiol 288:C100-C108.
9. 2+ channel properties in smooth muscle cells of the urinary bladder from pig and human. Eur J Pharmacol 443:19-29.
10. Madersbacher H, Halaska M, Voigt R, Alloussi S, and Höfner K (1999) A placebocontrolled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84:646-651.
11. Madersbacher H and Murtz G (2001) Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 19:324-335.
12. Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, et al. (2006) Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol 175: 365-369.
13. Meng E, Young JS, and Brading AF (2007) Spontaneous activity of mouse detrusor smooth muscle and the effects of the urothelium. Neurourol Urodyn, in press.
14. Michel MC and Hegde SS (2006) Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? Naunyn Schmiedebergs Arch Pharmacol 374:79-85.
15. 2+ release in the muscarinic-mediated contraction of mammalian urinary bladder smooth muscle. BJU Int 98:868-875.
16. 2+ sources. J Pharmacol Exp Ther 308:47-53.
17. Siepmann M, Nokhodian A, Thümmler D, and Kirch W (1998) Pharmacokinetics and safety of propiverine in patients with fatty liver disease. Eur J Clin Pharmacol 54:767-771.
18. Teramoto N and Brading AF (1996) Activation by levcromakalim and metabolic inhibition of glibenclamide-sensitive K channels in smooth muscle cells of pig proximal urethra. Br J Pharmacol 118:635-642.
19. 2+ channels in smooth muscle cells from pig proximal urethra. Br J Pharmacol 144:919-925.
20. Thomas EA and Ehlert FJ (1992) Irreversible effects of 4-DAMP mustard on muscarinic receptors in vivo. Proc West Pharmacol Soc 35:233-237.
21. Tokuno H, Chowdhury JU, and Tomita T (1993) Inhibitory effects of propiverine on rat and guinea-pig urinary bladder muscle. Naunyn Schmiedebergs Arch Pharmacol 348:659-662.
22. Uchida S, Kurosawa S, Fujino Oki T, Kato Y, Nanri M, Yoshida K, and Yamada S (2007) Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain. Life Sci 80:2454-2460.
23. Wang P, Luthin GR, and Ruggieri MR (1995) Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 273:959-966.
24. 3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes. J Pharmacol Exp Ther 237:419-427.
25. Wegener JW, Schulla V, Lee TS, Koller A, Feil S, Feil R, Kleppisch T, Klugbauer N, Moosmang S, Welling A, et al. (2004) An essential role of CaV1.2 L-type calcium channel for urinary bladder function. FASEB J 18:1159-1161.
26. Wuest M, Hecht J, Christ T, Braeter M, Schoeberl C, Hakenberg OW, Wirth MP, and Ravens U (2005) Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Br J Pharmacol 145:608-619.
27. 2+ influx to carbachol-induced detrusor contraction is different in human urinary bladder compared to pig and mouse. Eur J Pharmacol 565:180-189.
28. Wuest M, Weiss A, Waelbroeck M, Braeter M, Kelly LU, Hakenberg OW, and Ravens U (2006) Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol 374:87-97.
29. Yamaguchi O, Shisda K, Tamura K, Ogawa T, Fujimura T, and Ohtsuka M (1996) Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J Urol 156:1208-1213.